Katie Ellias

JDRF T1D Fund (JDRF T1D Fund) is a venture capital subsidiary of JDRF International founded in 2011 by Sean Doherty. The firm is headquartered in Boston, Massachusetts.

Capillary Biomedical, Inc. develops medical devices for diabetes management. The company was founded by Jeffrey Joseph and Paul Strasma and is headquartered in Irvine, CA.

Tech Health Experts provides technical support services.

Endeavour Vision SA (EV) is an independent venture capital firm headquartered in Geneva. EV traces their origins back to 1989 through the convergence of the Vision Capital European team and the Swiss VC firm, Endeavour. EV was co-founded in 2000 by Sven Lingjaerde and Damien Tappy. The firm specializes in providing funding for entrepreneurs in life sciences, biotech, medtech, cleantech and information technology. EV operates in close cooperation with Genevest, an independent investment vehicle which has reached the divestment stage. Their investors in the funds they advise are industrial corporations, family offices, global institutional investors and business leaders in the technology and investment industry.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

DiogenX SAS engages in the discovery and development of biologics therapeutics options of Diabetic patients. It operates in Diabetes preclinical stage business segment. The company was founded by Benjamin Charles, Patrick Collombat and Jean Pascal Tranié on December 24, 2019 and is headquartered in Marseille, France.

I2o Therapeutics, Inc. develops injection pills for biological therapies. It offers revolutionary oral delivery platform such as high bioavailability, low cost of goods, superior drug loading, injection free delivery, readily scalable, and compatible with diverse drug types. The company was founded by Samir Mitragotri, Ravi Srinivasan, Kelly Ibsen, and Tyler Brown in 2019 and is headquartered in Allston, MA.

Veralox Therapeutics, Inc. develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. The company was founded by Jeffrey W. Strovel, David J. Maloney and Matthew B. Boxer and is headquartered in Frederick, MD.